Edition:
United Kingdom

AstraZeneca PLC (AZN.L)

AZN.L on London Stock Exchange

6,250.00GBp
17 Jun 2019
Change (% chg)

35.00 (+0.56%)
Prev Close
6,215.00
Open
6,212.00
Day's High
6,258.00
Day's Low
6,162.00
Volume
1,345,809
Avg. Vol
2,137,101
52-wk High
6,540.00
52-wk Low
5,110.00

About

AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on discovery and development of products, which are then manufactured, marketed and sold. The Company focuses on three main therapy areas: Oncology, Cardiovascular & Metabolic Disease (CVMD) and Respiratory, while selectively pursuing therapies in... (more)

Overall

Beta: 1.04
Market Cap(Mil.): £65,514.78
Shares Outstanding(Mil.): 1,265.91
Dividend: 68.90
Yield (%): --

Financials

  AZN.L Industry Sector
P/E (TTM): 22.12 29.30 32.55
EPS (TTM): 2.34 -- --
ROI: 7.86 14.23 13.82
ROE: 28.47 15.46 15.24

Pfizer makes $10.6 billion cancer bet in cash deal for Array Biopharma

Pfizer Inc said on Monday it would buy Array Biopharma Inc for $10.64 billion in cash, a deal it hopes will help make it a leader in colon cancer and build up its pipeline of oncology drugs.

12:09am BST

UPDATE 5-Pfizer makes $10.6 bln cancer bet in cash deal for Array Biopharma

June 17 Pfizer Inc said on Monday it would buy Array Biopharma Inc for $10.64 billion in cash, a deal it hopes will help make it a leader in colon cancer and build up its pipeline of oncology drugs.

12:03am BST

GSK pharma head flags need for speed in high-pressure drug market

LONDON Doing things one at a time in drug development is not a luxury that GlaxoSmithKline can afford any longer, the head of pharmaceuticals at Britain's largest drugmaker told Reuters.

17 Jun 2019

GSK pharma head flags need for speed in high-pressure drug market

LONDON Doing things one at a time in drug development is not a luxury that GlaxoSmithKline can afford any longer, the head of pharmaceuticals at Britain's largest drugmaker told Reuters.

17 Jun 2019

GSK pharma head flags need for speed in high-pressure drug market

LONDON, June 17 Doing things one at a time in drug development is not a luxury that GlaxoSmithKline can afford any longer, the head of pharmaceuticals at Britain's largest drugmaker told Reuters.

17 Jun 2019

AstraZeneca's blood cancer drug meets main goal in late-stage trial

AstraZeneca Plc said on Thursday its blood cancer drug met the main goal of a final stage trial, taking the treatment one step closer to a marketing approval as the drugmaker seeks to bolster its oncology portfolio.

06 Jun 2019

AstraZeneca's blood cancer drug meets main goal in late-stage trial

AstraZeneca Plc said on Thursday its blood cancer drug met the main goal of a final stage trial, taking the treatment one step closer to a marketing approval as the drugmaker seeks to bolster its oncology portfolio.

06 Jun 2019

UPDATE 1-AstraZeneca's blood cancer drug meets main goal in late-stage trial

June 6 AstraZeneca Plc said on Thursday its blood cancer drug met the main goal of a final stage trial, taking the treatment one step closer to a marketing approval as the drugmaker seeks to bolster its oncology portfolio.

06 Jun 2019

AstraZeneca's blood cancer drug meets main goal in late-stage trial

June 6 AstraZeneca Plc said on Thursday its blood cancer drug met the primary endpoint of a final stage trial, the second success for the treatment in a month.

06 Jun 2019

AstraZeneca searches for successor to Chairman Johansson - Sky News

British drugmaker AstraZeneca Plc is preparing to search for a successor to Chairman Leif Johansson, Sky News reported on Monday.

03 Jun 2019

Earnings vs. Estimates